Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) EBT (2022 - 2025)

Taysha Gene Therapies' EBT history spans 4 years, with the latest figure at -$30.9 million for Q3 2025.

  • For Q3 2025, EBT fell 29.62% year-over-year to -$30.9 million; the TTM value through Sep 2025 reached -$94.1 million, down 15.66%, while the annual FY2024 figure was -$84.6 million, 14.56% down from the prior year.
  • EBT for Q3 2025 was -$30.9 million at Taysha Gene Therapies, down from -$24.9 million in the prior quarter.
  • Across five years, EBT topped out at -$15.0 million in Q4 2023 and bottomed at -$55.1 million in Q4 2022.
  • The 4-year median for EBT is -$23.8 million (2024), against an average of -$26.7 million.
  • The largest annual shift saw EBT skyrocketed 72.69% in 2023 before it tumbled 43.36% in 2024.
  • A 4-year view of EBT shows it stood at -$55.1 million in 2022, then skyrocketed by 72.69% to -$15.0 million in 2023, then decreased by 21.39% to -$18.3 million in 2024, then plummeted by 69.11% to -$30.9 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's EBT are -$30.9 million (Q3 2025), -$24.9 million (Q2 2025), and -$20.1 million (Q1 2025).